CartiHeal closed a US $18.3MM financing round. Funds will support the recently-approved Investigational Device Exemption clinical trial of the Agili-C™ implant, in pursuit of a Premarket Approval.
The two-year pivotal U.S./ex-U.S. study seeks to demonstrate superiority of the Agili-C™ implant vs. surgical standard of care in the treatment of cartilage and osteochondral defects in the joints.
The investment was led by aMoon with existing investors Johnson & Johnson Innovation, Peregrine Ventures and Elron.
Sources: CartiHeal Ltd.; ORTHOWORLD Inc.